News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Almirall Begins Aclidinium Tests to Get FDA Okay
April 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, April 30 (Reuters) - Spanish drug maker Almirall (ALM.MC) said on Thursday it had begun a programme to comply with U.S. and EU authorities' recommendations regarding phase III trials of lung drug aclidinium bromide.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
·
3 min read
·
Nick Paul Taylor
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
February 23, 2026
·
4 min read
·
Annalee Armstrong
Insights
Historic ALS Investment Signals New Treatment Momentum
February 23, 2026
·
3 min read
·
Jennifer Smith-Parker
MASH
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play
February 23, 2026
·
6 min read
·
Ben Hargreaves